

disorder comprising combining a compound with a polypeptide, are elected for prosecution without traverse.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II-IV in this or subsequent applications.

### **Preliminary Amendment**

#### **In the Claims:**

Please amend claims 1, 4, and 6. Please cancel claims 8-22, and add claims 23 and 24. This listing of the claims replaces all prior versions and listings of claims in the applications:

1. (Currently Amended): A method for identifying a candidate compound capable of treating a urological disorder, comprising:

a) combining a compound to be tested with a sample comprising a 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603, 2395, 2554, 8675, 32720, 4809, 14303, 16816, 17827, 32620, 577, 619, 1423, 2158, 8263, 15402, 16209, 16386, 21165, 30911, 41897, 1643, 2543, 9626, 13231, 32409, 84260, 2882, 8203, 32678 or 55053 polypeptide selected from the group consisting of:

i) a polypeptide comprising the amino acid sequence of SEQ ID NO:104; and

ii) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:103;

under conditions suitable for binding of the test compound to the polypeptide; and

b) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide[.,,];  
thereby identifying a compound capable of treating a urological disorder.

2. (Previously Presented): The method of claim 1, wherein the compound is selected from the group consisting of a small molecule, a peptide or an antibody.

3. (Previously Presented): The method of claim 1, wherein the polypeptide further comprises heterologous sequences.

4. (Amended): The method of claim 1, wherein the ~~polypeptide is~~ sample comprises an isolated polypeptide, a membrane-bound form of an isolated polypeptide or a cell comprising the polypeptide.

5. (Previously Presented): The method of claim 4, wherein the cell is a urological cell.

6. (Amended): The method of claim 1, wherein the urological disorder is a disorder associated with ~~U~~urinary incontinence or ~~BPH~~benign prostatic hyperplasia.

7. (Previously Presented): The method of claim 1, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:

- a) a competition binding assay;
- b) an immunoassay; and
- c) a yeast two-hybrid assay.

8-22. (Canceled)

23. (New): The method of claim 1, wherein binding of the test compound to the polypeptide is detected by an assay for an activity of the polypeptide.

24. (New): The method of claim 23, wherein the assay for activity is selected from the group consisting of:

- a) a carboxypeptidase assay; and
- b) an assay for measuring proteolysis of extracellular peptides or proteins.